Global Information
회사소개 | 문의

중국의 로수바스타틴(Rosuvastatin) 시장(2018-2022년)

Investigation Report on China´s Rosuvastatin Market, 2018-2022

리서치사 China Research and Intelligence
발행일 2018년 11월 상품 코드 333488
페이지 정보 영문 30 Pages
가격
US $ 2,200 ₩ 2,506,600 Unprintable PDF (Single User License)
US $ 3,300 ₩ 3,760,000 Printable & Editable PDF (Enterprisewide License)


중국의 로수바스타틴(Rosuvastatin) 시장(2018-2022년) Investigation Report on China´s Rosuvastatin Market, 2018-2022
발행일 : 2018년 11월 페이지 정보 : 영문 30 Pages

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

중국의 로수바스타틴(Rosuvastatin) 시장에 대해 조사 분석했으며, 시장 규모, 시장 점유율, 소매 가격, 주요 제조업체, 시장 전망 등의 정보를 전해드립니다.

제1장 로수바스타틴 관련 개념

  • 적응
  • 세계 시장에서의 판매 현황

제2장 중국의 로수바스타틴 시장 개요

  • 중국의 로수바스타틴 특허 및 승인 현황
  • 주요 제조업체
  • 시장 규모

제3장 로수바스타틴 판매 현황 분석

  • 판매액
  • 판매량

제4장 로수바스타틴 주요 제조업체의 중국 시장 점유율 분석

  • 시장 점유율 : 판매액별
  • 시장 점유율 : 판매량별

제5장 중국의 제형별 로수바스타틴 분석

  • 시장 점유율(제형별) : 판매액별
  • 시장 점유율(제형별) : 판매량별

제6장 로수바스타틴의 병원용 기준가격

  • IPR Pharmaceuticals
  • Nanjing Simcere Dongyuan Pharmaceutical Co., Ltd.
  • Nanjing Chia Tai Tianqing
  • Zhejiang Jingxin Pharmaceutical Co., Ltd
  • Lunan Better Pharmaceutical Co., Ltd

제7장 중국의 로수바스타틴 주요 제조업체

  • Lunan Better Pharmaceutical Co., Ltd
  • Nanjing Chia Tai Tianqing
  • Nanjing Simcere Dongyuan Pharmaceutical Co., Ltd.
  • Zhejiang Jingxin Pharmaceutical Co., Ltd
  • AstraZeneca plc.

제8장 중국의 로수바스타틴 시장 전망

  • 시장 규모 예측
  • 경쟁 구도 예측

도표

LSH 15.07.07

Description

Rosuvastatin was first developed by Japanese company Shionogi & Co., Ltd. in the late 1980s. In Jun. 1998, Shionogi & Co., Ltd. transferred the right to develop, market and sell Rosuvastatin worldwide to AstraZeneca. The development code of Rosuvastatin by AstraZeneca is ZD-4522. Rosuvastatin was first approved in the Netherlands on Nov. 7, 2002, approved by the Health Council of Canada in Feb. 2003, and by the FDA on Aug. 12, 2003. The trade name of AstraZeneca's branded Rosuvastatin is Crestor.

After Rosuvastatin was launched, its sales value grew sharply. Rosuvastatin has become a key product of statins. In 2012, Rosuvastatin became the number one lipid-lowering drug in the world with a sales value of USD 6.2 billion.

With the improvement of living standards and the change in diet, from 1978 to 2018, Chinese people's blood lipid levels kept rising, and the incidence of dyslipidemia increased significantly. The overall incidence of dyslipidemia in Chinese adults is up to about 40%. As dyslipidemia is a major cause of the development of coronary heart disease, strokes and other atherosclerotic lesions, active treatment of hyperlipidemia can reduce the incidence of these diseases. In China, Rosuvastatin is used to treat primary hypercholesterolemia (Type IIa, including heterozygous familial hypercholesterolemia) or mixed dyslipidemia (Type IIb) that cannot be properly controlled via diet control and non-drug treatments (e.g. sports therapy and weight loss). In the treatment of homozygous familial hypercholesterolemia, it complements the diet control and other lipid-lowering measures (such as LDL removal), or serves as an alternative when these measures do not work.

According to CRI, Rosuvastatin has been growing rapidly since it entered China, with its sales revenue increasing from less than CNY 2 million in 2007 to more than CNY 1.1 billion in 2017. At present, China's Rosuvastatin market is dominated by IPR PHARMACEUTICALS INC. (ASTRAZENECA), Lunan Better Pharmaceutical Co., Ltd., Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd., Nanjing Simcere Dongyuan Pharmaceutical Co., Ltd., Zhejiang Jingxin Pharmaceutical Co., Ltd., etc. Pfizer has the largest market share by sales value which was about 67% in 2017.

It is expected that as more Chinese people suffer from hyperlipidemia, China's Rosuvastatin market will continue to grow in the next few years.

Topics Covered:

  • Situation of hyperlipidemia in China
  • Market size of Rosuvastatin in China
  • Competitive landscape of China's Rosuvastatin market
  • Prices of Rosuvastatin in China
  • Prospect of China's Rosuvastatin market from 2018 to 2022

Table of Contents

Table of Contents

1 Relevant Concepts of Rosuvastatin

  • 1.1 Indications for Rosuvastatin
  • 1.2 Development of Rosuvastatin in China
  • 1.3 Patents and Government Approval on Rosuvastatin in China

2 Sales of Rosuvastatin in China, 2013-2017

  • 2.1 Sales Value of Rosuvastatin
    • 2.1.1 Overall Sales Value
    • 2.1.2 Sales Value by Region
  • 2.2 Sales Volume of Rosuvastatin
    • 2.2.1 Overall Sales Volume
    • 2.2.2 Sales Volume by Region
  • 2.3 Sales of Rosuvastatin by Dosage Form in China, 2013-2017
    • 2.3.1 Tablets
    • 2.3.2 Capsules

3 Analysis on Major Rosuvastatin Manufacturers in China, 2013-2017

  • 3.1 Analysis on Market Share of Major Rosuvastatin Manufacturers
    • 3.1.1 Market Share by Sales Value
    • 3.1.2 Market Share by Sales Volume
  • 3.2 IPR PHARMACEUTICALS INC.(ASTRAZENECA)
    • 3.2.1 Enterprise Profile
    • 3.2.2 Sales of Rosuvastatin by IPR PHARMACEUTICALS INC.(ASTRAZENECA) in China
  • 3.3 Lunan Better Pharmaceutical Co., Ltd.
    • 3.3.1 Enterprise Profile
    • 3.3.2 Sales of Rosuvastatin by Lunan Better Pharmaceutical Co., Ltd. in China
  • 3.4 Zhejiang Jingxin Pharmaceutical Co., Ltd.
  • 3.5 Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd.
  • 3.6 Nanjing Simcere Dongyuan Pharmaceutical Co., Ltd.

4 Prices of Rosuvastatin in China, 2017-2018

  • 4.1 IPR PHARMACEUTICALS INC.(ASTRAZENECA)(Crestor)
  • 4.2 Lunan Better Pharmaceutical Co., Ltd. (Ruizhi)
  • 4.3 Zhejiang Jingxin Pharmaceutical Co., Ltd. (Jingnuo)
  • 4.4 Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd. (Tuotuo)
  • 4.5 Nanjing Simcere Dongyuan Pharmaceutical Co., Ltd. (Shufutan)

5 Prospect of China's Rosuvastatin Market, 2018-2022

  • 5.1 Forecast on Market Size
  • 5.2 Forecast on Market Trend

Selected Charts

  • Chart Government Approval of Rosuvastatin in China
  • Chart Sales Value of Rosuvastatin in China, 2013-2017
  • Chart Sales Value of Rosuvastatin in Parts of China, 2013-2017
  • Chart Sales Volume of Rosuvastatin in China, 2013-2017
  • Chart Sales Volume of Rosuvastatin in Parts of China, 2013-2017
  • Chart Sales Value of Rosuvastatin Tablets in China, 2013-2017
  • Chart Sales Value of Rosuvastatin Capsules in China, 2013-2017
  • Chart Market Share of Top 5 Rosuvastatin Manufacturers by Sales Value, 2013-2017
  • Chart Market Share of Top 5 Rosuvastatin Manufacturers by Sales Volume, 2013-2017
  • Chart Sales Value of Rosuvastatin by IPR PHARMACEUTICALS INC.(ASTRAZENECA), 2013-2017
  • Chart Sales Volume of Rosuvastatin by IPR PHARMACEUTICALS INC.(ASTRAZENECA), 2013-2017
  • Chart Sales Value of Rosuvastatin by Lunan Better Pharmaceutical Co., Ltd., 2013-2017
  • Chart Sales Volume of Rosuvastatin by Lunan Better Pharmaceutical Co., Ltd., 2013-2017
  • Chart Sales Value of Rosuvastatin by Zhejiang Jingxin Pharmaceutical Co., Ltd., 2013-2017
  • Chart Sales Value of Rosuvastatin by Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd., 2013-2017
  • Chart Prices of Rosuvastatin (Crestor) by IPR PHARMACEUTICALS INC.(ASTRAZENECA) in Parts of China, 2017-2018
  • Chart Prices of Rosuvastatin (Ruizhi) by Lunan Better Pharmaceutical Co., Ltd. in Parts of China, 2017-2018
  • Chart Prices of Rosuvastatin (Jingnuo) by Zhejiang Jingxin Pharmaceutical Co., Ltd. in Parts of China, 2017-2018
  • Chart Prices of Rosuvastatin (Tuotuo) by Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd. in Parts of China, 2017-2018
  • Chart Prices of Rosuvastatin (Shufutan) by Nanjing Simcere Dongyuan Pharmaceutical Co., Ltd. in Parts of China, 2017-2018
  • Chart Forecast on Sales Value of Rosuvastatin in China, 2018-2022
Back to Top
전화 문의
이용안내
 
BCC Research